The selection of CAR-T cell targets for the treatment of HNSCC is usually based on the following two prerequisites: (1) CAR-T cell target proteins that have been reported in the treatment of solid tumors, such as FAP and GD2; (2) proteins that are highly expressed on the surface of HNSCC cells and are rarely expressed in normal tissues. This evidence concerns the gene FAP and head and neck squamous cell carcinoma.